Shares of aTyr Pharma LIFE rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 69.48% over the past year to ($0.47), which beat the estimate of ($0.82).
Revenue of $2,053,000 higher by 1325.69% from the same period last year, which beat the estimate of $130,000.
Looking Ahead
aTyr Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Mar 23, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/rpx2ex5c
Price Action
52-week high: $8.33
52-week low: $2.40
Price action over last quarter: Up 72.19%
Company Profile
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
